Skip to main content
Journal cover image

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Publication ,  Journal Article
Guptill, JT; Soni, M; Meriggioli, MN
Published in: Neurotherapeutics
January 2016

Myasthenia gravis (MG) is an autoimmune disease associated with the production of autoantibodies against 1) the skeletal muscle acetylcholine receptor; 2) muscle-specific kinase, a receptor tyrosine kinase critical for the maintenance of neuromuscular synapses; 3) low-density lipoprotein receptor-related protein 4, an important molecular binding partner for muscle-specific kinase; and 4) other muscle endplate proteins. In addition to the profile of autoantibodies, MG may be classified according the location of the affected muscles (ocular vs generalized), the age of symptom onset, and the nature of thymic pathology. Immunopathologic events leading to the production of autoantibodies differ in the various disease subtypes. Advances in our knowledge of the immunopathogenesis of the subtypes of MG will allow for directed utilization of the ever-growing repertoire of therapeutic agents that target distinct nodes in the immune pathway relevant to the initiation and maintenance of autoimmune disease. In this review, we examine the pathogenesis of MG subtypes, current treatment options, and emerging new treatments and therapeutic targets.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurotherapeutics

DOI

EISSN

1878-7479

Publication Date

January 2016

Volume

13

Issue

1

Start / End Page

118 / 131

Location

United States

Related Subject Headings

  • Translational Research, Biomedical
  • T-Lymphocytes
  • Plasma Cells
  • Neurology & Neurosurgery
  • Myasthenia Gravis
  • Humans
  • Complement Inactivating Agents
  • B-Lymphocytes
  • 5202 Biological psychology
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Guptill, J. T., Soni, M., & Meriggioli, M. N. (2016). Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics, 13(1), 118–131. https://doi.org/10.1007/s13311-015-0398-y
Guptill, Jeffrey T., Madhu Soni, and Matthew N. Meriggioli. “Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Neurotherapeutics 13, no. 1 (January 2016): 118–31. https://doi.org/10.1007/s13311-015-0398-y.
Guptill JT, Soni M, Meriggioli MN. Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan;13(1):118–31.
Guptill, Jeffrey T., et al. “Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Neurotherapeutics, vol. 13, no. 1, Jan. 2016, pp. 118–31. Pubmed, doi:10.1007/s13311-015-0398-y.
Guptill JT, Soni M, Meriggioli MN. Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan;13(1):118–131.
Journal cover image

Published In

Neurotherapeutics

DOI

EISSN

1878-7479

Publication Date

January 2016

Volume

13

Issue

1

Start / End Page

118 / 131

Location

United States

Related Subject Headings

  • Translational Research, Biomedical
  • T-Lymphocytes
  • Plasma Cells
  • Neurology & Neurosurgery
  • Myasthenia Gravis
  • Humans
  • Complement Inactivating Agents
  • B-Lymphocytes
  • 5202 Biological psychology
  • 3214 Pharmacology and pharmaceutical sciences